Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Melanoma of the Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of ocular melanoma~  * No melanoma of the iris~* Disease adequately treated by prior surgery (enucleation or tumorectomy) and/or radiotherapy~  * No more than 5 weeks since the beginning of primary tumor treatment~* Measurable disease~  * At least 12.0 mm in largest diameter OR~ * At least 6.0 mm in height~* HLA-A2 positive~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* ECOG 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Hemoglobin at least 9 g/dL~* Neutrophil count at least 2,000/mm\^3~* Lymphocyte count at least 700/mm\^3~* Platelet count at least 100,000/mm\^3~* No bleeding disorder~Hepatic:~* Bilirubin no greater than 2.0 mg/dL~* AST and ALT no greater than 2 times upper limit of normal (ULN)~* Lactate dehydrogenase no greater than 2 times ULN~* Alkaline phosphatase no greater than 2 times ULN~* Gamma glutamyl transpeptidases no greater than 2 times ULN~* Hepatitis C antibody negative~* Hepatitis B antigen negative~Renal:~* Creatinine no greater than 2.0 mg/dL~Immunologic:~* No clinical immunodeficiency~* No autoimmune diseases~* No inflammatory bowel disease~* No active infection requiring antibiotics~* No multiple sclerosis~Other:~* HIV negative~* No other malignancy except surgically cured carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin~* No other uncontrolled illness~* No psychological, familial, sociological, or geographical conditions that would preclude study participation~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 3 months after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No other concurrent immunotherapy or biologic therapy~Chemotherapy:~* No concurrent chemotherapy~Endocrine therapy:~* At least 3 weeks since prior steroids~* No concurrent chronic therapy with high doses of corticosteroids (e.g., methylprednisolone at least 12 mg/day)~* Concurrent topical or inhalation steroids allowed~* No concurrent hormonal therapy~Radiotherapy:~* See Disease Characteristics~* Prior proton beam therapy allowed~* Prior brachytherapy without tumor resection allowed~* Recovered from prior radiotherapy~* No prior radiotherapy to the spleen~* No prior pre-enucleation radiotherapy~* No prior ruthenium Ru 106 as primary therapy alone~* No concurrent radiotherapy~Surgery:~* See Disease Characteristics~* Prior transcleral tumor resection allowed~* Recovered from prior surgery~* No prior major organ allograft~* No prior splenectomy~Other:~* No other concurrent investigational drugs~* No concurrent systemic immunosuppressive drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues